Prerpints.org logo
Preprint
Article

Acute Effect of Positive Airway Pressure on Heart Rate Variability in Obstructive Sleep Apnea

Altmetrics

Downloads

96

Views

27

Comments

0

A peer-reviewed article of this preprint also exists.

This version is not peer-reviewed

Submitted:

08 November 2023

Posted:

09 November 2023

You are already at the latest version

Alerts
Abstract
Autonomic dysregulation is associated with cardiovascular consequences in obstructive sleep apnea (OSA). This study aimed to investigate the effect of acute continuous positive airway pressure (CPAP) treatment on autonomic activity and to identify factors contributing to the heart rate variability (HRV) changes in OSA. Frequency domain HRV parameters were calculated and compared between the baseline polysomnography and during the CPAP titration in 402 patients with moderate to severe OSA. There were significant reductions in total power, very low-frequency band power, low-frequency band power, and high-frequency band power during the CPAP titration as compared to the baseline polysomnography. This tendency was more pronounced in men than in women, and in patients with severe OSA than those with moderate OSA. Multivariate analysis found that changes in apnea-hypopnea index and oxygen saturation were significantly associated with changes in sympathetic and parasympathetic activity, respectively. This study demonstrated that HRV parameters significantly changed during the CPAP titration, indicating a beneficial effect of CPAP in restoration of sympathetic and parasympathetic hyperactivity in OSA. Prospective longitudinal studies should determine whether long-term CPAP treatment aids in maintaining the long-lasting improvement of the autonomic functions, thereby contributing to the prevention of cardiovascular and cerebrovascular diseases in patients with OSA.
Keywords: 
Subject: Medicine and Pharmacology  -   Neuroscience and Neurology

1. Introduction

Recent epidemiological studies have indicated that obstructive sleep apnea (OSA) is an independent risk factor for stroke, hypertension, atrial fibrillation, coronary artery disease, heart failure, and sudden cardiac death [1,2,3]. The exact mechanism underlying this link is not fully elucidated; however, recent studies have shown that OSA patients frequently exhibit excessive activation of the sympathetic nervous system, suggesting a role of disturbed cardiac autonomic regulation in the development of cardiovascular and cerebrovascular diseases [4,5,6]. Frequent respiratory events during sleep, including intermittent hypoxemia, hypercapnia, intrathoracic pressure change, and recurrent arousals, alter the sympathovagal balance toward sympathetic hyperactivity [7,8]. Meanwhile, the impact of OSA on parasympathetic modulation during sleep remains controversial [9].
It has been proposed that both sympathetic and parasympathetic systems are physiologically co-activated in individuals with OSA [10]. The interaction between these two systems in relation to the heart may not always follow a reciprocal pattern [11]. A decrease in arterial partial pressure of oxygen or an increase in arterial partial pressure of carbon dioxide may lead to simultaneous activation of sympathetic and parasympathetic activities, which disrupts the reciprocal interaction between the two activities [11]. Respiratory collapse, hypoxia, and recurrent arousals could lead to parasympathetic hyperactivity during apneic events, followed by sympathetic hyperactivity in patients with OSA. The initial stage of apneic events, characterized by resistive breathing without accompanying hypoxemia, may exhibit heightened parasympathetic tone [12]. Increased inspiratory effort gives rise to a reduction in parasympathetic tone and an elevation in sympathetic tone at the termination of apnea [13].
Heart rate is regulated by sympathetic and parasympathetic activities, and heart rate variability (HRV) serves as a simple and useful method for assessing cardiac autonomic functions [14,15]. Previous studies analyzing HRV have shown alterations in sympathetic or parasympathetic activity in patients with OSA [16,17,18,19,20,21,22,23,24]. Both low-frequency power (LF) and LF-to-high-frequency power (HF) ratio consistently increased in OSA patients compared to healthy controls, pointing to a shift in the sympathovagal balance toward sympathetic hyperactivity [17,19,20,21,22,23,25,26,27,28,29]. Meanwhile, other studies have yielded somewhat inconsistent findings with regard to HF, an HRV parameter reflecting parasympathetic activity: decreased HF [10,22,23,26,27,28,29,30,31,32,33,34] or increased HF [17,35,36,37] in OSA patients when compared to controls.
There is mounting evidence that continuous positive airway pressure (CPAP) treatment improves HRV in patients with OSA [29,34,38,39,40,41,42,43,44]. A significant decrease in sympathetic hyperactivity, as assessed by HRV, was demonstrated both on the first night of CPAP titration [34,41,43] and after long-term CPAP treatment [29,34,39,44]. In contrast, the effect of CPAP treatment on parasympathetic activity has yielded inconsistent results across the studies [29,34,38,39,40,42,43,45,46,47].
The present study aimed 1) to determine whether acute CPAP treatment can modify HRV alterations and restore abnormal sympathetic and parasympathetic activity, and 2) to identify independent factors affecting HRV alterations while controlling for potential confounding factors. We hypothesize that not only LF reflecting sympathetic activity but also HF reflecting parasympathetic activity is decreased during acute CPAP treatment by way of correcting hypoxemia in patients with OSA.

2. Materials and Methods

2.1. Study population

We retrospectively studied 548 patients with moderate to severe OSA who underwent overnight polysomnography (PSG) and consecutive PSG for CPAP titration at the sleep center of Korea University Guro Hospital between 2011 to 2022. Patients with a history of stroke, myocardial infarction, atrial fibrillation, angina pectoris, and hyperthyroidism were excluded. Patients with other sleep disorders that can influence the autonomic function, such as rapid eye movement (REM) sleep behavior disorder, restless legs syndrome, and narcolepsy [48], were further excluded from the analysis. All patients included in the final analysis did not take any anticholinergic (e.g., atropine, benztropine, trihexyphenidyl), sympathomimetic (e.g., epinephrine, phenylephrine, isoproterenol, salbutamol) or parasympathomimetic (e.g., bethanechol, pilocarpine) medications. All patients completed the Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale, and SF-36 quality of life questionnaires.

2.2. Polysomnography

An overnight PSG recording was conducted using Embla N7000 system (Natus Medical Inc., Pleasanton, CA, USA). Electroencephalography was recorded using four pairs of leads (C4-A1, C3-A2, O2-A1, and O1-A2) with two pairs of electro-oculographic leads. Electromyographic leads were attached to the tibialis anterior and submentalis muscles. Airflow was continuously monitored using a thermistor and a nasal pressure cannula, and arterial oxygen saturation was measured via a pulse oximeter. Respiratory motions were tracked with the use of inductive plethysmographic belts wrapped tightly around both the abdomen and chest.
Sleep stages and events were evaluated and scored based on the guidelines established by the American Academy of Sleep Medicine [49]. The parameters related to sleep architecture were the following: total sleep time, time spent in bed, sleep latency, wake after sleep onset, stage 1 sleep, stage 2 sleep, slow-wave sleep, REM sleep, sleep efficiency, and arousal. The arousal index (AI) was determined as the total number of arousals per hour, calculated by adding the periodic limb movement AI, apnea-hypopnea AI, and spontaneous AI. The oxygen desaturation index was determined by counting the number of events in which oxygen saturation decreased by 4% or more per hour. Apnea was characterized as a reduction in airflow ≥ 90% of baseline for a minimum duration of 10 seconds. Hypopnea was characterized by a reduction in airflow ≥ 30% of baseline for a minimum duration of 10 seconds, accompanied by either an arousal or a 3% decrease in oxygen saturation [49]. The apnea-hypopnea index (AHI) was determined by the number of apnea-hypopnea events per hour of recorded sleep time. Patients were classified into mild OSA (5 ≤ AHI < 15), moderate OSA (15 ≤ AHI < 30), and severe OSA (AHI ≥ 30) groups.

2.3. Heart rate variability

The electrocardiography data retrieved from the whole overnight PSG recording were visually inspected for quality and reliability, and then used for HRV analysis. Artefacts and ectopic beats were automatically removed, and only normal-to-normal beats were chosen for HRV analysis [50]. The assessment of HRV comprises time domain and frequency domain analyses. The time domain HRV parameters quantify the amount of variability in beat-to-beat intervals, and are influenced by both sympathetic and parasympathetic activities. Consequently, these parameters cannot differentiate the specific roles of sympathetic and parasympathetic activities in autonomic nervous system functions [14]. The frequency domain HRV parameters are measured by using the fast Fourier transform and classified into different frequency ranges with associated spectral powers. This process offers information regarding specific alterations in sympathetic and parasympathetic activity [14]. We focused on the frequency domain parameters to better evaluate autonomic function changes by distinguishing between sympathetic and parasympathetic activity. The following parameters were calculated for spectral analysis executed in RemLogic software (Version 2.0; Embla Co., Broomfield, USA): (1) total power spectrum (TP), (2) high-frequency band power (HF; 0.15–0.40 Hz), (3) low-frequency band power (LF; 0.04–0.15 Hz), and (4) very low-frequency band power (VLF; 0.0033–0.04 Hz). HF and LF are generally accepted to reflect parasympathetic activity and baroreflex-mediated sympathetic activity, respectively [50]. The LF/HF ratio is recognized as the representative index of sympathetic to parasympathetic (sympathovagal) balance with a higher LF/HF indicating sympathetic hyperactivity [50]. TP and VLF overall reflect a measure of autonomic function and parasympathetic activity, respectively.

2.4. Statistical analysis

Descriptive statistics illustrated the baseline characteristics and PSG parameters of the study population. Within-group comparisons of HRV parameters changes between the baseline PSG and during CPAP titration were made using paired t-test. This analysis was repeated for subgroups related to sex (male and female patients) and disease severity (moderate OSA and severe OSA patients). Multivariate linear regression analysis was performed to assess significant associations between the independent variables (e.g., demographics, changes in PSG variables) and dependent variables (changes in frequency domain HRV parameters). The effect of multicollinearity between the independent variables was assessed using variance inflation factors. Only variables with variance inflation factor < 5 entered into multivariate linear regression analysis as independent variables. Statistical significance was set at p < 0.05 in all tests. Statistical analyses were performed with the Statistical Package for the Social Sciences software (Version 26.0; IBM Corp., Armonk, New York, USA).

3. Results

Of 548 patients with moderate to severe OSA, 146 were excluded due to medical history of stroke (n = 36), angina pectoris (n = 53), atrial fibrillation (n = 17), REM sleep behavior disorder (n = 21), restless legs syndrome (n = 12), and narcolepsy (n = 7). Demographics, clinical characteristics, sleep questionnaires, and PSG parameters of the 402 patients (320 males and 82 females, 132 moderate OSA and 270 severe OSA) are summarized in Table 1.
Table 2 summarizes the details of the PSG parameters and HRV parameters of the baseline PSG and during the CPAP titration as well as their corresponding statistical results. Waking after sleep onset (t = 4.0), N1 sleep (t = 19.2), AHI (t = 39.6), oxygen desaturation index (t = 35.0), and AI (t = 30.6) significantly decreased during the CPAP titration when compared to the baseline PSG (all p < 0.001). Sleep efficiency (t = –4.0), N2 sleep (t = –7.8), N3 sleep (t = –4.5), REM sleep (t = –7.8), and mean arterial oxygen saturation (t = –9.9) significantly increased during the CPAP titration when compared to the baseline PSG (all p < 0.001). The following frequency domain HRV parameters significantly decreased during the CPAP titration as compared to the baseline PSG: TP (t = 5.5, p < 0.001), VLF (t = 5.5, p < 0.001), LF (t = 3.0, p = 0.003), and HF (t = 4.2, p < 0.001). There was no significant change in LF/HF ratio between the baseline PSG and CPAP titration (p = 0.395).
Results of the subgroup analyses related to sex and disease severity are summarized in Table 3. In male patients, all frequency domain HRV parameters significantly decreased during the CPAP titration compared to the baseline PSG: TP (t = 5.1, p < 0.001), VLF (t = 5.2, p < 0.001), LF (t = 2.8, p = 0.005), and HF (t = 3.6, p < 0.001). In female patients, TP (t = 2.1, p = 0.039) and HF (t = 2.4, p = 0.018) significantly decreased during the CPAP titration compared to the baseline PSG. Different to the male patients, VLF and LF did not significantly change during the CPAP titration (both p > 0.05). In patients with moderate OSA, HF significantly decreased during the CPAP titration compared to the baseline PSG (t = 2.6, p = 0.010), while TP, VLF, LF, and LF/HF ratio did not significantly change (all p > 0.05). Patients with severe OSA had significant changes in the following parameters between the baseline PSG and during the CPAP titration: TP (t = 5.6, p < 0.001), VLF (t = 5.4, p < 0.001), LF (t = 3.7, p < 0.001), and HF (t = 3.3, p = 0.001).
Table 4 summarizes the results of multivariate linear regression analysis for significant associations between the independent variables and changes in frequency domain HRV parameters. Changes in TP significantly correlated with changes in AHI (t = 2.2, p = 0.025) and BMI (t = 2.0, p = 0.042). Changes in VLF significantly correlated with changes in AHI (t = 2.3, p = 0.024) and age (t = 2.3, p = 0.024). Changes in LF significantly correlated with changes in AHI (t = 2.0, p = 0.044) and BMI (t = 2.8, p = 0.006). Changes in HF significantly correlated with changes in mean arterial oxygen saturation (t = 5.0, p < 0.001) and age (t = –2.2, p = 0.032).

4. Discussion

In the present study, we aimed to determine whether acute CPAP treatment can improve HRV in patients with moderate to severe OSA. The main findings are that HRV parameters significantly changed during the CPAP titration, indicating an important role of CPAP treatment in restoration of sympathetic and parasympathetic hyperactivity in patients with OSA. This tendency was more pronounced in men than in women, and in patients with severe OSA compared to those with moderate OSA. Multivariate linear regression analysis found that changes in AHI and mean arterial oxygen saturation are significantly associated with changes in sympathetic and parasympathetic activity, respectively.
Previous studies have examined the effect of CPAP on sympathetic hyperactivity in OSA patients, and repeatedly demonstrated a significant reduction in LF during both acute CPAP treatment [34,41,43] and long-term CPAP treatment [29,34,39]. In a prospective longitudinal study, HRV was analyzed during the first night of CPAP treatment and after 2 years of CPAP treatment in 30 patients with moderate to severe OSA [34]. Both acute and long-term CPAP treatment decreased the LF during non-REM and REM sleep, indicating a beneficial role of CPAP treatment on sympathetic hyperactivity in OSA [34]. A meta-analysis including 11 studies found a significant decrease in LF in OSA patients receiving CPAP treatment for a duration ranging from 1 month to over 12 months, suggesting that long-term CPAP treatment potentially improves cardiac autonomic function [51]. Another meta-analysis including 17 studies found a tendency toward a small decrease in sympathetic measures of HRV with various treatments for OSA [9]. Heterogeneity in HRV measures (LF, normalized LF, and LF/HF ratio) and treatment modalities (e.g., CPAP, mandibular advancement device, and oral jaw-positioning appliance) may introduce potential confounding factors in the results. In line with the aforementioned studies, our large-scale study demonstrated a significant reduction in LF during acute CPAP treatment compared to the baseline. This trend of significantly reduced LF was more pronounced in men than in women, and in patients with severe OSA compared to those with moderate OSA. Similar to our study, 16 patients with severe OSA showed a significant reduction in LF during acute CPAP treatment in both REM and non-REM sleep, while 14 patients with moderate OSA did not [34], implying that the increased OSA severity may lead to a heightened effectiveness of acute CPAP treatment in restoring normal sympathetic activity. Taken together, CPAP treatment may have the potential to improve sympathetic hyperactivity observed in patients with OSA. However, the finding of reduced LF following CPAP treatment was not replicated in previous studies investigating the same paradigm. No statistically significant change in LF was observed in moderate to severe OSA patients receiving 3 months CPAP treatment [45,47].
It is generally considered that CPAP treatment decreases sympathetic activity while increasing parasympathetic activity, exhibiting opposing yet complementary effects on these two activities. The impact of CPAP treatment on parasympathetic activity has also been examined in OSA, with inconsistent results across the studies. Several currently available studies have reported a significant increase in HF (i.e., increased parasympathetic activity) during both acute CPAP treatment [34,43] and long-term CPAP treatment [29,34,40,42]. However, no significant change in HF was found in moderate to severe OSA patients receiving 3 months CPAP treatment, compared to the baseline [45,46]. There was no overall change in parasympathetic measures of HRV following CPAP treatment in a meta-analysis including 19 studies [9]. This discrepancy warrants the need for a prospective longitudinal study to further investigate the issue of HF alteration with CPAP treatment.
The sympathetic nervous system is known as the "fight or flight" system associated with high arousal and activity, while the parasympathetic nervous system is regarded as the "rest and digest" system linked to relaxation and recovery [52]. Sympathetic and parasympathetic activities appear to have contrasting and reciprocal roles, implying that when one activity increases, the other activity typically decreases. Meanwhile, mild hypoxia causes a co-activation of both cardiac sympathetic and vagal nerve activities [11,53]. Upper airway obstruction observed in OSA patients may increase parasympathetic activity and, in turn, cause hypoxia, resulting in an abrupt increase in sympathetic activity [12,44]. In the healthy population, it is well documented that increased parasympathetic activity and decreased sympathetic activity are typically observed during non-REM sleep, whereas the opposite occurs during REM sleep [54,55,56,57,58]. Patients with OSA exhibit a similar pattern, while they tend to show more pronounced parasympathetic activity during sleep [36,44,59]. Moderate to severe OSA patients showed greater parasympathetic activation during non-REM sleep compared to mild OSA patients and non-OSA controls, indicating a positive association between apnea severity and parasympathetic activity [60]. An increase in parasympathetic activity may be linked to an increase in hydraulic pressure [60], which could be initiated by the carotid aortic chemoreceptor in response to hypoxemia [61,62]. Patients with OSA displayed a noteworthy decrease in HF with CPAP treatment compared to their baseline measurements [38,41,63]. Our finding of a significant decrease in HF during CPAP titration in moderate to severe OSA patients accords well with those of previous studies, suggesting that CPAP treatment may improve HRV by way of reducing not only sympathetic activity but also parasympathetic activity.
It is widely recognized that OSA is linked to an increased incidence of cardiovascular and cerebrovascular diseases [64,65]. Previous studies provided compelling evidence that untreated moderate to severe OSA in patients with established coronary disease [66,67,68] and heart failure [69] is associated with increased cardiovascular and cerebrovascular morbidity and mortality. Data from small-scale trials provide evidence that treatment of OSA with CPAP improves cardiovascular outcomes such as lowering blood pressure and reducing incidence of repeat revascularization, myocardial infarction, and stroke [64,70,71]. A long-term observational study clearly demonstrated that the incidence of fatal and non-fatal cardiovascular and cerebrovascular events in untreated patients with severe OSA is significantly higher than that in untreated mild-moderate OSA patients and in healthy participants who were individually matched for BMI and age [65]. Notably, treatment with CPAP significantly reduced cardiovascular and cerebrovascular risks in patients with severe OSA, and this reduction was not significantly different from that observed in healthy participants [65]. It is previously assumed that long-term CPAP treatment partially reduces sympathetic hyperactivity and restores the impaired sympathovagal balance in OSA patients [72,73], which may be one of the potential mechanisms in preventing the development of cardiovascular diseases [74,75]. Our finding that acute CPAP treatment reduced both sympathetic and parasympathetic activity provides a theoretical framework supporting the notion that CPAP treatment may contribute to the reduction of cardiovascular and cerebrovascular diseases.
This study has several strengths. First, a substantial number of patients were enrolled, ensuring statistical reliability due to the large sample size. Second, we utilized multivariate linear regression analysis to identify the variables associated with the observed HRV differences. Changes in LF were closely related to changes in AHI, suggesting that AHI is an important contributing factor for changes in sympathetic activity induced by CPAP treatment in OSA. We also found a significant correlation between changes in HF and changes in mean arterial oxygen saturation, implying that hypoxia, independent of apnea, is associated with alterations in parasympathetic activity. This study has also several potential limitations that should be addressed. First, the inclusion of patients who were referred to a university-affiliated hospital may introduce a selection bias, limiting the generalizability of the findings to the entire OSA population. Second, we did not exclude patients with comorbidities that may affect autonomic functions, such as hypertension [76], diabetes mellitus [77], or obesity [78]. Nevertheless, a within-subject design employed in this study can help mitigate the influence of comorbidity issue on autonomic measurements. Third, HRV alterations observed during the CPAP titration may result from changes in venous return secondary to the substantial intrathoracic pressure fluctuations during the apneic events rather than the changes in cardiovascular control mechanisms. Thus, the influence of CPAP treatment on autonomic alterations in OSA patients may be better assessed by comparing baseline HRV parameters with those obtained after several weeks of CPAP treatment, rather than those obtained during acute CPAP treatment. Last, technical limitations in HRV analysis may arise from the use of HRV data obtained from the entire overnight PSG recording without excluding arousals and apneas, which can alter HRV parameters.

5. Conclusions

In conclusion, we have shown that acute CPAP treatment restores sympathetic and parasympathetic hyperactivity, suggesting a beneficial effect of CPAP on autonomic functions in patients with moderate to severe OSA. Given the close relationship between autonomic alterations and increased risks of cardiovascular and cerebrovascular diseases in OSA, prospective longitudinal studies are warranted to determine whether long-term CPAP treatment aids in maintaining the longstanding improvement of the autonomic functions, thereby contributing to the prevention of such consequences.

Author Contributions

Conceptualization, J.H.S. and J.H.K.; methodology, J.H.S. and M.J.S.; validation, J.H.S., M.J.S., and J.H.K.; formal analysis, J.H.S. and J.H.K.; data curation, J.H.S. and M.J.S.; writing—original draft preparation, J.H.S.; writing—review and editing, J.H.K.; supervision, J.H.K.; funding acquisition, J.H.K. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the National Research Foundation of Korea Grant funded by the Korean Government (Grant No. NRF-2018R1D1A1B07048207). The funder did not have any role in the study design, data collection, analysis and interpretation of data, or writing the manuscript.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of Korea University Guro Hospital.

Informed Consent Statement

Informed consent of the participants was not required, as this was a retrospective analysis of data from routine clinical practice.

Data Availability Statement

The dataset used and analyzed in the current study is available from the corresponding author on reasonable request.

Acknowledgments

The authors are grateful to all participants for their voluntary participation and compliance with the study protocol.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Tietjens, J.R.; Claman, D.; Kezirian, E.J.; De Marco, T.; Mirzayan, A.; Sadroonri, B.; Goldberg, A.N.; Long, C.; Gerstenfeld, E.P.; Yeghiazarians, Y. Obstructive Sleep Apnea in Cardiovascular Disease: A Review of the Literature and Proposed Multidisciplinary Clinical Management Strategy. J Am Heart Assoc 2019, 8, e010440. [Google Scholar] [CrossRef] [PubMed]
  2. Roux, F.; D'Ambrosio, C.; Mohsenin, V. Sleep-related breathing disorders and cardiovascular disease. Am J Med 2000, 108, 396–402. [Google Scholar] [CrossRef] [PubMed]
  3. Yaggi, H.K.; Concato, J.; Kernan, W.N.; Lichtman, J.H.; Brass, L.M.; Mohsenin, V. Obstructive sleep apnea as a risk factor for stroke and death. New Engl J Med 2005, 353, 2034–2041. [Google Scholar] [CrossRef] [PubMed]
  4. Bauters, F.; Rietzschel, E.R.; Hertegonne, K.B.C.; Chirinos, J.A. The Link Between Obstructive Sleep Apnea and Cardiovascular Disease. Current Atherosclerosis Reports 2016, 18. [Google Scholar] [CrossRef]
  5. Parish, J.M.; Somers, V.K. Obstructive sleep apnea and cardiovascular disease. Mayo Clin Proc 2004, 79, 1036–1046. [Google Scholar] [CrossRef] [PubMed]
  6. Durgan, D.J.; Bryan, R.M., Jr. Cerebrovascular consequences of obstructive sleep apnea. J Am Heart Assoc 2012, 1, e000091. [Google Scholar] [CrossRef] [PubMed]
  7. Dewan, N.A.; Nieto, F.J.; Somers, V.K. Intermittent hypoxemia and OSA: implications for comorbidities. Chest 2015, 147, 266–274. [Google Scholar] [CrossRef] [PubMed]
  8. Turnbull, C.D. Intermittent hypoxia, cardiovascular disease and obstructive sleep apnoea. J Thorac Dis 2018, 10, S33–S39. [Google Scholar] [CrossRef] [PubMed]
  9. Dissanayake, H.U.; Bin, Y.S.; Sutherland, K.; Ucak, S.; de Chazal, P.; Cistulli, P.A. The effect of obstructive sleep apnea therapy on cardiovascular autonomic function: a systematic review and meta-analysis. Sleep 2022, 45. [Google Scholar] [CrossRef]
  10. Tobaldini, E.; Nobili, L.; Strada, S.; Casali, K.R.; Braghiroli, A.; Montano, N. Heart rate variability in normal and pathological sleep. Front Physiol 2013, 4, 294. [Google Scholar] [CrossRef]
  11. Koizumi, K.; Terui, N.; Kollai, M. Neural control of the heart: significance of double innervation re-examined. J Auton Nerv Syst 1983, 7, 279–294. [Google Scholar] [CrossRef] [PubMed]
  12. Guilleminault, C.; Poyares, D.; Rosa, A.; Huang, Y.S. Heart rate variability, sympathetic and vagal balance and EEG arousals in upper airway resistance and mild obstructive sleep apnea syndromes. Sleep Med 2005, 6, 451–457. [Google Scholar] [CrossRef]
  13. Bisogni, V.; Pengo, M.F.; Maiolino, G.; Rossi, G.P. The sympathetic nervous system and catecholamines metabolism in obstructive sleep apnoea. J Thorac Dis 2016, 8, 243–254. [Google Scholar] [CrossRef] [PubMed]
  14. Rajendra Acharya, U.; Paul Joseph, K.; Kannathal, N.; Lim, C.M.; Suri, J.S. Heart rate variability: a review. Med Biol Eng Comput 2006, 44, 1031–1051. [Google Scholar] [CrossRef] [PubMed]
  15. Pumprla, J.; Howorka, K.; Groves, D.; Chester, M.; Nolan, J. Functional assessment of heart rate variability: physiological basis and practical applications. Int J Cardiol 2002, 84, 1–14. [Google Scholar] [CrossRef] [PubMed]
  16. Roche, F.; Gaspoz, J.M.; Court-Fortune, I.; Minini, P.; Pichot, V.; Duverney, D.; Costes, F.; Lacour, J.R.; Barthelemy, J.C. Screening of obstructive sleep apnea syndrome by heart rate variability analysis. Circulation 1999, 100, 1411–1415. [Google Scholar] [CrossRef] [PubMed]
  17. Gula, L.J.; Krahn, A.D.; Skanes, A.; Ferguson, K.A.; George, C.; Yee, R.; Klein, G.J. Heart rate variability in obstructive sleep apnea: a prospective study and frequency domain analysis. Ann Noninvasive Electrocardiol 2003, 8, 144–149. [Google Scholar] [CrossRef] [PubMed]
  18. Lado, M.J.; Mendez, A.J.; Rodriguez-Linares, L.; Otero, A.; Vila, X.A. Nocturnal evolution of heart rate variability indices in sleep apnea. Comput Biol Med 2012, 42, 1179–1185. [Google Scholar] [CrossRef] [PubMed]
  19. Zhu, K.; Chemla, D.; Roisman, G.; Mao, W.; Bazizi, S.; Lefevre, A.; Escourrou, P. Overnight heart rate variability in patients with obstructive sleep apnoea: a time and frequency domain study. Clin Exp Pharmacol Physiol 2012, 39, 901–908. [Google Scholar] [CrossRef]
  20. Park, D.H.; Shin, C.J.; Hong, S.C.; Yu, J.; Ryu, S.H.; Kim, E.J.; Shin, H.B.; Shin, B.H. Correlation between the severity of obstructive sleep apnea and heart rate variability indices. Journal of Korean Medical Science 2008, 23, 226–231. [Google Scholar] [CrossRef]
  21. Kim, Y.S.; Kim, S.Y.; Park, D.Y.; Wu, H.W.; Hwang, G.S.; Kim, H.J. Clinical Implication of Heart Rate Variability in Obstructive Sleep Apnea Syndrome Patients. J Craniofac Surg 2015, 26, 1592–1595. [Google Scholar] [CrossRef] [PubMed]
  22. Narkiewicz, K.; Montano, N.; Cogliati, C.; van de Borne, P.J.; Dyken, M.E.; Somers, V.K. Altered cardiovascular variability in obstructive sleep apnea. Circulation 1998, 98, 1071–1077. [Google Scholar] [CrossRef] [PubMed]
  23. Aydin, M.; Altin, R.; Ozeren, A.; Kart, L.; Bilge, M.; Unalacak, M. Cardiac autonomic activity in obstructive sleep apnea: time-dependent and spectral analysis of heart rate variability using 24-hour Holter electrocardiograms. Tex Heart Inst J 2004, 31, 132–136. [Google Scholar] [PubMed]
  24. Sun, J.; Li, X.; Guo, J.; Han, F.; Zhang, H. Identification of obstructive sleep apnea syndrome by ambulatory electrocardiography: clinical evaluation of time-domain and frequency-domain analyses of heart rate variability in Chinese patients. Cell Biochem Biophys 2011, 59, 165–170. [Google Scholar] [CrossRef] [PubMed]
  25. Jurysta, F.; Lanquart, J.P.; van de Borne, P.; Migeotte, P.F.; Dumont, M.; Degaute, J.P.; Linkowski, P. The link between cardiac autonomic activity and sleep delta power is altered in men with sleep apnea-hypopnea syndrome. Am J Physiol Regul Integr Comp Physiol 2006, 291, R1165–R1171. [Google Scholar] [CrossRef] [PubMed]
  26. Hilton, M.F.; Chappell, M.J.; Bartlett, W.A.; Malhotra, A.; Beattie, J.M.; Cayton, R.M. The sleep apnoea/hypopnoea syndrome depresses waking vagal tone independent of sympathetic activation. Eur Respir J 2001, 17, 1258–1266. [Google Scholar] [CrossRef] [PubMed]
  27. Li, X.; Covassin, N.; Zhou, J.; Zhang, Y.; Ren, R.; Yang, L.; Tan, L.; Li, T.; Xue, P.; Tang, X. Interaction effect of obstructive sleep apnea and periodic limb movements during sleep on heart rate variability. J Sleep Res 2019, 28, e12861. [Google Scholar] [CrossRef]
  28. Palma, J.A.; Urrestarazu, E.; Lopez-Azcarate, J.; Alegre, M.; Fernandez, S.; Artieda, J.; Iriarte, J. Increased sympathetic and decreased parasympathetic cardiac tone in patients with sleep related alveolar hypoventilation. Sleep 2013, 36, 933–940. [Google Scholar] [CrossRef] [PubMed]
  29. Chang, J.S.; Lee, S.D.; Ju, G.; Kim, J.W.; Ha, K.; Yoon, I.Y. Enhanced cardiorespiratory coupling in patients with obstructive sleep apnea following continuous positive airway pressure treatment. Sleep Med 2013, 14, 1132–1138. [Google Scholar] [CrossRef]
  30. Khoo, M.C.; Kim, T.S.; Berry, R.B. Spectral indices of cardiac autonomic function in obstructive sleep apnea. Sleep 1999, 22, 443–451. [Google Scholar] [CrossRef]
  31. Wiklund, U.; Olofsson, B.O.; Franklin, K.; Blom, H.; Bjerle, P.; Niklasson, U. Autonomic cardiovascular regulation in patients with obstructive sleep apnoea: a study based on spectral analysis of heart rate variability. Clin Physiol 2000, 20, 234–241. [Google Scholar] [CrossRef] [PubMed]
  32. Pan, W.Y.; Su, M.C.; Wu, H.T.; Su, T.J.; Lin, M.C.; Sun, C.K. Multiscale entropic assessment of autonomic dysfunction in patients with obstructive sleep apnea and therapeutic impact of continuous positive airway pressure treatment. Sleep Med 2016, 20, 12–17. [Google Scholar] [CrossRef] [PubMed]
  33. Roche, F.; Gaspoz, J.M.; Court-Fortune, I.; Costes, F.; Geyssant, A.; Duverney, D.; Pichot, V.; Barthelemy, J.C. Alteration of QT rate dependence reflects cardiac autonomic imbalance in patients with obstructive sleep apnea syndrome. Pacing Clin Electrophysiol 2003, 26, 1446–1453. [Google Scholar] [CrossRef] [PubMed]
  34. Palma, J.A.; Iriarte, J.; Fernandez, S.; Alegre, M.; Valencia, M.; Artieda, J.; Urrestarazu, E. Long-term continuous positive airway pressure therapy improves cardiac autonomic tone during sleep in patients with obstructive sleep apnea. Clin Auton Res 2015, 25, 225–232. [Google Scholar] [CrossRef] [PubMed]
  35. Aytemir, K.; Deniz, A.; Yavuz, B.; Ugur Demir, A.; Sahiner, L.; Ciftci, O.; Tokgozoglu, L.; Can, I.; Sahin, A.; Oto, A. Increased myocardial vulnerability and autonomic nervous system imbalance in obstructive sleep apnea syndrome. Respir Med 2007, 101, 1277–1282. [Google Scholar] [CrossRef] [PubMed]
  36. Salsone, M.; Vescio, B.; Quattrone, A.; Roccia, F.; Sturniolo, M.; Bono, F.; Aguglia, U.; Gambardella, A.; Quattrone, A. Cardiac parasympathetic index identifies subjects with adult obstructive sleep apnea: A simultaneous polysomnographic-heart rate variability study. PLoS One 2018, 13, e0193879. [Google Scholar] [CrossRef] [PubMed]
  37. Coruzzi, P.; Gualerzi, M.; Bernkopf, E.; Brambilla, L.; Brambilla, V.; Broia, V.; Lombardi, C.; Parati, G. Autonomic cardiac modulation in obstructive sleep apnea: effect of an oral jaw-positioning appliance. Chest 2006, 130, 1362–1368. [Google Scholar] [CrossRef] [PubMed]
  38. Dal-Fabbro, C.; Garbuio, S.; D'Almeida, V.; Cintra, F.D.; Tufik, S.; Bittencourt, L. Mandibular advancement device and CPAP upon cardiovascular parameters in OSA. Sleep Breath 2014, 18, 749–759. [Google Scholar] [CrossRef]
  39. Roche, F.; Court-Fortune, I.; Pichot, V.; Duverney, D.; Costes, F.; Emonot, A.; Vergnon, J.M.; Geyssant, A.; Lacour, J.R.; Barthelemy, J.C. Reduced cardiac sympathetic autonomic tone after long-term nasal continuous positive airway pressure in obstructive sleep apnoea syndrome. Clin Physiol 1999, 19, 127–134. [Google Scholar] [CrossRef]
  40. Tasali, E.; Chapotot, F.; Leproult, R.; Whitmore, H.; Ehrmann, D.A. Treatment of obstructive sleep apnea improves cardiometabolic function in young obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2011, 96, 365–374. [Google Scholar] [CrossRef]
  41. Salsone, M.; Marelli, S.; Vescio, B.; Quattrone, A.; Gambardella, A.; Castelnuovo, A.; Quattrone, A.; Ferini Strambi, L. Usefulness of cardiac parasympathetic index in CPAP-treated patients with obstructive sleep apnea: A preliminary study. J Sleep Res 2020, 29, e12893. [Google Scholar] [CrossRef]
  42. Kuramoto, E.; Kinami, S.; Ishida, Y.; Shiotani, H.; Nishimura, Y. Continuous positive nasal airway pressure decreases levels of serum amyloid A and improves autonomic function in obstructive sleep apnea syndrome. Int J Cardiol 2009, 135, 338–345. [Google Scholar] [CrossRef]
  43. Efazati, N.; Rahimi, B.; Mirdamadi, M.; Edalatifard, M.; Tavoosi, A. Changes in heart rate variability (HRV) in patients with severe and moderate obstructive sleep apnea before and after acute CPAP therapy during nocturnal polysomnography. Sleep Sci 2020, 13, 97–102. [Google Scholar] [CrossRef]
  44. Chrysostomakis, S.I.; Simantirakis, E.N.; Schiza, S.E.; Karalis, I.K.; Klapsinos, N.C.; Siafakas, N.M.; Vardas, P.E. Continuous positive airway pressure therapy lowers vagal tone in patients with obstructive sleep apnoea-hypopnoea syndrome. Hellenic J Cardiol 2006, 47, 13–20. [Google Scholar] [PubMed]
  45. Shiina, K.; Tomiyama, H.; Takata, Y.; Yoshida, M.; Kato, K.; Saruhara, H.; Hashimura, Y.; Matsumoto, C.; Asano, K.; Usui, Y.; Yamashina, A. Effects of CPAP therapy on the sympathovagal balance and arterial stiffness in obstructive sleep apnea. Resp Med 2010, 104, 911–916. [Google Scholar] [CrossRef]
  46. Glos, M.; Penzel, T.; Schoebel, C.; Nitzsche, G.R.; Zimmermann, S.; Rudolph, C.; Blau, A.; Baumann, G.; Jost-Brinkmann, P.G.; Rautengarten, S.; et al. Comparison of effects of OSA treatment by MAD and by CPAP on cardiac autonomic function during daytime. Sleep Breath 2016, 20, 635–646. [Google Scholar] [CrossRef] [PubMed]
  47. Ferland, A.; Poirier, P.; Series, F. Sibutramine versus continuous positive airway pressure in obese obstructive sleep apnoea patients. Eur Respir J 2009, 34, 694–701. [Google Scholar] [CrossRef]
  48. Miglis, M.G. Autonomic dysfunction in primary sleep disorders. Sleep Med 2016, 19, 40–49. [Google Scholar] [CrossRef] [PubMed]
  49. Berry, R.B.; Brooks, R.; Gamaldo, C.; Harding, S.M.; Lloyd, R.M.; Quan, S.F.; Troester, M.T.; Vaughn, B.V. AASM Scoring Manual Updates for 2017 (Version 2.4). J Clin Sleep Med 2017, 13, 665–666. [Google Scholar] [CrossRef]
  50. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1996, 93, 1043–1065. [CrossRef]
  51. Guo, W.; Lv, T.; She, F.; Miao, G.; Liu, Y.; He, R.; Xue, Y.; Nu, N.K.; Yang, J.; Li, K.; Zhang, P. The impact of continuous positive airway pressure on heart rate variability in obstructive sleep apnea patients during sleep: A meta-analysis. Heart Lung 2018, 47, 516–524. [Google Scholar] [CrossRef] [PubMed]
  52. Berntson, G.G.; Cacioppo, J.T.; Quigley, K.S. Autonomic determinism: the modes of autonomic control, the doctrine of autonomic space, and the laws of autonomic constraint. Psychol Rev 1991, 98, 459–487. [Google Scholar] [CrossRef] [PubMed]
  53. Paton, J.F.; Boscan, P.; Pickering, A.E.; Nalivaiko, E. The yin and yang of cardiac autonomic control: vago-sympathetic interactions revisited. Brain Res Brain Res Rev 2005, 49, 555–565. [Google Scholar] [CrossRef] [PubMed]
  54. Cabiddu, R.; Cerutti, S.; Viardot, G.; Werner, S.; Bianchi, A.M. Modulation of the Sympatho-Vagal Balance during Sleep: Frequency Domain Study of Heart Rate Variability and Respiration. Front Physiol 2012, 3, 45. [Google Scholar] [CrossRef] [PubMed]
  55. Otzenberger, H.; Gronfier, C.; Simon, C.; Charloux, A.; Ehrhart, J.; Piquard, F.; Brandenberger, G. Dynamic heart rate variability: a tool for exploring sympathovagal balance continuously during sleep in men. Am J Physiol 1998, 275, H946–H950. [Google Scholar] [CrossRef] [PubMed]
  56. Vanoli, E.; Adamson, P.B.; Ba, L.; Pinna, G.D.; Lazzara, R.; Orr, W.C. Heart rate variability during specific sleep stages. A comparison of healthy subjects with patients after myocardial infarction. Circulation 1995, 91, 1918–1922. [Google Scholar] [CrossRef] [PubMed]
  57. Zemaityte, D.; Varoneckas, G.; Sokolov, E. Heart rhythm control during sleep. Psychophysiology 1984, 21, 279–289. [Google Scholar] [CrossRef]
  58. Bonnet, M.H.; Arand, D.L. Heart rate variability: sleep stage, time of night, and arousal influences. Electroencephalogr Clin Neurophysiol 1997, 102, 390–396. [Google Scholar] [CrossRef]
  59. Gammoudi, N.; Ben Cheikh, R.; Saafi, M.A.; Sakly, G.; Dogui, M. Cardiac autonomic control in the obstructive sleep apnea. Libyan J Med 2015, 10, 26989. [Google Scholar] [CrossRef]
  60. da Silva, S.P.; Hulce, V.D.; Backs, R.W. Effects of obstructive sleep apnea on autonomic cardiac control during sleep. Sleep Breath 2009, 13, 147–156. [Google Scholar] [CrossRef]
  61. Remsburg, S.; Launois, S.H.; Weiss, J.W. Patients with obstructive sleep apnea have an abnormal peripheral vascular response to hypoxia. J Appl Physiol 1999, 87, 1148–1153. [Google Scholar] [CrossRef] [PubMed]
  62. Sato, F.; Nishimura, M.; Shinano, H.; Saito, H.; Miyamoto, K.; Kawakami, Y. Heart rate during obstructive sleep apnea depends on individual hypoxic chemosensitivity of the carotid body. Circulation 1997, 96, 274–281. [Google Scholar] [PubMed]
  63. Yamaguchi, K.; Ohki, N.; Kobayashi, M.; Satoya, N.; Inoue, Y.; Onizawa, S.; Maeda, Y.; Sekiguchi, H.; Suzuki, M.; Tsuji, T.; et al. Estimation of parasympathetic nerve function during sleep in patients with obstructive sleep apnea by instantaneous time-frequency analysis. Sleep Med 2014, 15, 33–41. [Google Scholar] [CrossRef] [PubMed]
  64. Drager, L.F.; McEvoy, R.D.; Barbe, F.; Lorenzi-Filho, G.; Redline, S.; Initiative, I. Sleep Apnea and Cardiovascular Disease: Lessons From Recent Trials and Need for Team Science. Circulation 2017, 136, 1840–1850. [Google Scholar] [CrossRef]
  65. Marin, J.M.; Carrizo, S.J.; Vicente, E.; Agusti, A.G. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005, 365, 1046–1053. [Google Scholar] [CrossRef]
  66. Valham, F.; Mooe, T.; Rabben, T.; Stenlund, H.; Wiklund, U.; Franklin, K.A. Increased risk of stroke in patients with coronary artery disease and sleep apnea: a 10-year follow-up. Circulation 2008, 118, 955–960. [Google Scholar] [CrossRef] [PubMed]
  67. Lee, C.H.; Sethi, R.; Li, R.; Ho, H.H.; Hein, T.; Jim, M.H.; Loo, G.; Koo, C.Y.; Gao, X.F.; Chandra, S.; et al. Obstructive Sleep Apnea and Cardiovascular Events After Percutaneous Coronary Intervention. Circulation 2016, 133, 2008–2017. [Google Scholar] [CrossRef] [PubMed]
  68. Uchoa, C.H.G.; Danzi-Soares, N.J.; Nunes, F.S.; de Souza, A.A.L.; Nerbass, F.B.; Pedrosa, R.P.; Cesar, L.A.M.; Lorenzi-Filho, G.; Drager, L.F. Impact of OSA on cardiovascular events after coronary artery bypass surgery. Chest 2015, 147, 1352–1360. [Google Scholar] [CrossRef] [PubMed]
  69. Wang, H.; Parker, J.D.; Newton, G.E.; Floras, J.S.; Mak, S.; Chiu, K.L.; Ruttanaumpawan, P.; Tomlinson, G.; Bradley, T.D. Influence of obstructive sleep apnea on mortality in patients with heart failure. J Am Coll Cardiol 2007, 49, 1625–1631. [Google Scholar] [CrossRef]
  70. Gottlieb, D.J.; Punjabi, N.M.; Mehra, R.; Patel, S.R.; Quan, S.F.; Babineau, D.C.; Tracy, R.P.; Rueschman, M.; Blumenthal, R.S.; Lewis, E.F.; et al. CPAP versus oxygen in obstructive sleep apnea. N Engl J Med 2014, 370, 2276–2285. [Google Scholar] [CrossRef]
  71. Peker, Y.; Glantz, H.; Eulenburg, C.; Wegscheider, K.; Herlitz, J.; Thunstrom, E. Effect of Positive Airway Pressure on Cardiovascular Outcomes in Coronary Artery Disease Patients with Nonsleepy Obstructive Sleep Apnea. The RICCADSA Randomized Controlled Trial. Am J Respir Crit Care Med 2016, 194, 613–620. [Google Scholar] [CrossRef] [PubMed]
  72. Hedner, J.; Darpo, B.; Ejnell, H.; Carlson, J.; Caidahl, K. Reduction in sympathetic activity after long-term CPAP treatment in sleep apnoea: cardiovascular implications. Eur Respir J 1995, 8, 222–229. [Google Scholar] [CrossRef] [PubMed]
  73. Kohler, M.; Pepperell, J.C.; Casadei, B.; Craig, S.; Crosthwaite, N.; Stradling, J.R.; Davies, R.J. CPAP and measures of cardiovascular risk in males with OSAS. Eur Respir J 2008, 32, 1488–1496. [Google Scholar] [CrossRef] [PubMed]
  74. Penzel, T.; Riedl, M.; Gapelyuk, A.; Suhrbier, A.; Bretthauer, G.; Malberg, H.; Schobel, C.; Fietze, I.; Heitmann, J.; Kurths, J.; Wessel, N. Effect of CPAP therapy on daytime cardiovascular regulations in patients with obstructive sleep apnea. Comput Biol Med 2012, 42, 328–334. [Google Scholar] [CrossRef] [PubMed]
  75. Qureshi, W.T.; bin Nasir, U.; Alqalyoobi, S.; O'Neal, W.T.; Mawri, S.; Sabbagh, S.; Soliman, E.Z.; Al-Mallah, M.H. Meta-Analysis of Continuous Positive Airway Pressure as a Therapy of Atrial Fibrillation in Obstructive Sleep Apnea. Am J Cardiol 2015, 116, 1767–1773. [Google Scholar] [CrossRef]
  76. Wang, X.; Luo, J.; Huang, R.; Xiao, Y. The Elevated Central Chemosensitivity in Obstructive Sleep Apnea Patients with Hypertension. Nat Sci Sleep 2022, 14, 855–865. [Google Scholar] [CrossRef] [PubMed]
  77. Peltier, A.C.; Bagai, K.; Artibee, K.; Diedrich, A.; Garland, E.; Elasy, T.; Shi, Y.; Wang, L.; Feldman, E.L.; Robertson, D.; Malow, B.A. Effect of mild hyperglycemia on autonomic function in obstructive sleep apnea. Clin Auton Res 2012, 22, 1–8. [Google Scholar] [CrossRef]
  78. Reynolds, E.B.; Seda, G.; Ware, J.C.; Vinik, A.I.; Risk, M.R.; Fishback, N.F. Autonomic function in sleep apnea patients: increased heart rate variability except during REM sleep in obese patients. Sleep Breath 2007, 11, 53–60. [Google Scholar] [CrossRef]
Table 1. Clinical characteristics of the study population.
Table 1. Clinical characteristics of the study population.
Clinical characteristics
Male: Female, n (%) 320 (79.6 %): 82 (20.4 %)
Age, years 52.0 ± 11.8 (range = 16–81)
BMI (kg/m2) 28.8 ± 4.4 (range = 19–48.9)
Moderate: Severe OSA, n (%) 132 (32.8 %): 270 (67.2 %)
Hypertension, n (%) 228 (56.7 %)
Diabetes mellitus, n (%) 77 (19.2 %)
Current smoker, n (%) 91 (22.6 %)
ESS score 8.3 ± 4.6 (range = 0–24)
PSQI 7.5 ± 4.6 (range = 0–22)
SF-36 68.2 ± 19.4 (range = 15–98)
Abbreviations: BMI, body mass index; ESS, Epworth Sleepiness Scale score; PSQI, Pittsburgh Sleep Quality Index; SF-36, Medical Outcome Study 36-item short-form health survey, Values are expressed as mean ± standard deviation or number (percentage).
Table 2. PSG parameters and frequency domain HRV parameters of the baseline PSG and during the CPAP titration.
Table 2. PSG parameters and frequency domain HRV parameters of the baseline PSG and during the CPAP titration.
PSG parameters
Baseline During CPAP p Value
Total sleep time (min) 349.0 ± 48.8 349.8 ± 46.5 0.737
Sleep efficiency (%) 84.6 ± 10.7 86.7 ± 10.1 < 0.001
WASO (min) 53.3 ± 40.9 45.1 ± 38.1 < 0.001
N1 (min) 127.2 ± 56.3 68.2 ± 33.5 < 0.001
N2 (min) 126.5 ± 88.7 162.5 ± 45.2 < 0.001
N3 (min) 11.3 ± 19.2 15.6 ± 23.5 < 0.001
REM (min) 86.7 ± 33.3 103.5 ± 37.6 < 0.001
AHI 43.9 ± 22.0 2.6 ± 3.1 < 0.001
ODI 41.0 ± 22.3 3.5 ± 5.8 < 0.001
AI 50.7 ± 22.7 15.1 ± 12.4 < 0.001
Mean SaO2 (%) 93.7 ± 2.5 95.8 ± 1.2 < 0.001
Frequency domain HRV parameters
Baseline During CPAP p Value
TP (ms2) 39,836 ± 20,001 35,672 ± 17,055 < 0.001
VLF (ms2) 21,184 ± 12,586 18,494 ± 10,006 < 0.001
LF (ms2) 12,472 ± 7,636 11,560 ± 7,157 0.003
HF (ms2) 5,380 ± 2,917 4,920 ± 2,507 < 0.001
LF/HF ratio 2.9 ± 2.3 2.8 ± 2.2 0.395
Abbreviations: AHI, apnea-hypopnea index; AI, arousal index; HF, high-frequency power; LF, low-frequency power; ODI, oxygen desaturation index; REM, rapid eye movement; SaO2, mean arterial oxygen saturation; TP, total power; VLF, very low-frequency power; WASO, waking after sleep onset. Values are expressed as mean ± standard deviations.
Table 3. Results of the subgroup analysis related to sex and disease severity of changes in frequency domain HRV parameters between the baseline PSG and during the CPAP titration.
Table 3. Results of the subgroup analysis related to sex and disease severity of changes in frequency domain HRV parameters between the baseline PSG and during the CPAP titration.
Frequency domain HRV parameters
Male (n = 320) Female (n = 82)
Baseline During CPAP p Value Baseline During CPAP p Value
TP (ms2) 42,847 ± 20,249 38,191 ± 17,164 < 0.001 28,088 ± 13,788 25,843 ± 12,524 0.039
VLF (ms2) 22,987 ± 12,866 19,914 ± 10,050 < 0.001 14,147 ± 8,327 12,953 ± 7,674 0.068
LF (ms2) 13,581 ± 7,722 12,559 ± 7,312 0.005 8,140 ± 5,474 7,658 ± 4,866 0.317
HF (ms2) 5,478 ± 2,937 5,033 ± 2,601 < 0.001 4,996 ± 2,824 4,482 ± 2,059 0.018
LF/HF ratio 3.1 ± 2.4 3.0 ± 2.3 0.545 2.1 ± 2.1 2.0 ± 1.4 0.396
Moderate OSA (n = 132) Severe OSA (n = 270)
Baseline During CPAP p Value Baseline During CPAP p Value
TP (ms2) 36,916 ± 17,479 35,765 ± 16,710 0.271 41,264 ± 21,007 35,626 ± 17,252 < 0.001
VLF (ms2) 18,987 ± 10,003 18,127 ± 9,143 0.149 22,258 ± 13,561 18,673 ± 10,414 < 0.001
LF (ms2) 11,524 ± 7,296 11,775 ± 7,646 0.563 12,935 ± 7,768 11,454 ± 6,918 < 0.001
HF (ms2) 5,674 ± 2,967 5,191 ± 2,669 0.010 5,236 ± 2,887 4,788 ± 2,418 0.001
LF/HF ratio 2.4 ± 2.0 2.7 ± 2.5 0.082 3.1 ± 2.5 2.8 ± 2.0 0.073
Abbreviations. HF, high-frequency power; LF, low-frequency power; TP, total power; VLF, very low-frequency power. Values are expressed as mean ± standard deviations.
Table 4. Results of multivariate linear regression analysis for variables associated with changes in HRV parameters.
Table 4. Results of multivariate linear regression analysis for variables associated with changes in HRV parameters.
Multivariate linear regression analysis
Independent variables ∆ VLF ∆ LF ∆HF ∆TP
Age 0.129* 0.052 –0.119* 0.086
Sex –0.078 –0.015 0.007 –0.056
BMI 0.061 0.150** 0.084 0.112*
∆ AHI 0.188* 0.166* –0.025 0.186*
∆ AI –0.070 –0.047 –0.038 –0.069
∆ mean SaO2 –0.021 –0.038 0.312*** 0.013
Abbreviations. AHI, apnea hypopnea index; AI, arousal index; BMI, body mass index; HF, high-frequency power; LF, low-frequency power; SaO2, arterial oxygen saturation; TP, total power; VLF, very low-frequency power; ∆, the average amount of change. Values are expressed as standardized beta coefficients; *p < 0.05, **p < 0.01, ***p < 0.001.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated